Clinical trial
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NCT00108797 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00108797 |
|---|---|
| Title | Trial of NovoSeven® in Haemophilia - Joint Bleeds |
| Official title | NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA® |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors |
| Intervention type | Drug |
| Interventions | eptacog alfa (activated), Feiba VH |
| Enrollment | 42 |
| Start date | Sep 1, 2001 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2006 |
| First posted | Apr 19, 2005 |
| Last update posted | Jan 12, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: